STF-31 is a selective inhibitor of glucose transporter 1 (GLUT1), with an IC50 of 1μM.
IC50&Target
GLUT1
1 μM (IC50)
体外研究
STF-31 (0.01-10 μM; 10 days) is specifically toxic to RCC4 cells, whereas RCC4/VHL cells are relatively unaffected. RCC4/VHL cells treated with STF-31 (5 μM; 10 days) largely recovery, whereas RCC4 cells under the same conditions does not.
STF-31 (1.25-5 μM; 3 days) does not induce autophagy, apoptosis, or DNA damage. STF-31 causes a necrotic cell death.
Cell Viability Assay
Cell Line:
Wild-type RCC4 cells (RCC4/VHL) and RCC4 cells without VHL
Concentration:
0.01, 0.1, 1, 10 μM
Incubation Time:
10 days
Result:
Reduced viability of RCC4 cells without VHL in a concentration-dependent manner when compared to their wild-type counterparts.
体内研究
Soluble analog of STF-31 (11.6 mg/kg; i.p.) treatment delays tumor growth in mice with VHL-deficient RCC tumor xenografts.
STF-31 (10 mg/kg; i.p.; twice daily for 2 days, followed by once daily for another 3 days) does not affect normal mice body weight, behavior, and ERG responses. STF-31 reduces light-induced CX3CR1 mice microglial activation and retinal degeneration.
Animal Model:
Twelve-week old C57BL/6J and CX3CR1 mice
Dosage:
10 mg/kg
Administration:
I.p. injections; twice daily for 2 days, followed by once daily for another 3 days
Result:
Improved photoreceptor survival and reduced microglial activation of CX3CR1 mice, and not induced any C57BL/6J mice retinal cell death.
分子式
C23H25N3O3S
分子量
423.53
CAS号
724741-75-7
运输条件
Room temperature in continental US; may vary elsewhere.